We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

53 hedge funds and large institutions have $129M invested in Orchestra BioMed in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

10% more funds holding

Funds holding: 48 → 53 (+5)

7% more capital invested

Capital invested by funds: $121M → $129M (+$8.35M)

3.1% more ownership

Funds ownership: 59.66% → 62.75% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
53
Holders Change
+5
Holders Change %
+10.42%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
11
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$5.19M
2
WAM
Weiss Asset Management
Massachusetts
+$1.78M
3
KKRC
Kohlberg Kravis Roberts & Co
New York
+$1.67M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$1.48M
5
HI
HBK Investments
Texas
+$606K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.87M
2
IC
Ikarian Capital
Texas
-$1.95M
3
AC
Athanor Capital
New York
-$215K
4
BFM
Boothbay Fund Management
New York
-$169K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$89.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
DKCM
1
Davidson Kempner Capital Management
New York
$9.75M – – –
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$8.06M – – –
BlackRock
3
BlackRock
New York
$8.04M – – –
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$7.99M -$89.5K -9,082 -1%
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$7.79M +$5.19M +526,264 +208%
PI
6
Putnam Investments
Massachusetts
$7.5M – – –
RCM
7
RA Capital Management
Massachusetts
$6.3M – – –
AC
8
Amitell Capital
Singapore
$6.05M +$442K +44,869 +8%
O
9
OrbiMed
New York
$5.04M – – –
PA
10
Perceptive Advisors
New York
$4.54M – – –
KPF
11
K2 Principal Fund
Ontario, Canada
$4.29M +$51.2K +5,192 +1%
WP
12
Woodline Partners
California
$4.07M – – –
APM
13
Avidity Partners Management
Texas
$4.03M – – –
BC
14
Boxer Capital
California
$4.03M – – –
EC
15
EcoR1 Capital
California
$4.03M – – –
ACP
16
Acuta Capital Partners
California
$3.96M – – –
M
17
Murchinson
Ontario, Canada
$3.02M – – –
AAA
18
Affinity Asset Advisors
New York
$3M – – –
WAM
19
Weiss Asset Management
Massachusetts
$2.96M +$1.78M +180,482 +156%
Citadel Advisors
20
Citadel Advisors
Florida
$2.63M +$34.1K +3,457 +1%
GL
21
Governors Lane
New York
$2.52M – – –
SCM
22
Sio Capital Management
New York
$2.52M – – –
KKRC
23
Kohlberg Kravis Roberts & Co
New York
$1.7M +$1.67M +168,985 New
BFM
24
Boothbay Fund Management
New York
$1.67M -$169K -17,115 -9%
ASM
25
ATW SPAC Management
New York
$1.58M – – –
1
2 3

OBIO Hedge Fund Activity: Q4 2021 in Review

53 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q4 2021, worth a combined $129M — up 6.9% from $121M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new OBIO positions and 4 closed out — a net gain of 5 holders — while 11 added to existing stakes and 5 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $5.19M. The largest seller was Wellington Management Group, cutting an estimated $3.87M.

  • 53 institutional investors held Orchestra BioMed (OBIO) as of Q4 2021, up from 48 in Q3 2021.
  • Funds reported $129M of Orchestra BioMed stock for Q4 2021, up 6.9% quarter-over-quarter.
  • 9 funds opened new Orchestra BioMed positions in Q4 2021 and 4 closed out, a net change of +5 holders.
  • The largest Orchestra BioMed buyer in Q4 2021 was D.E. Shaw & Co, an estimated $5.19M added.
  • The largest Orchestra BioMed seller in Q4 2021 was Wellington Management Group, an estimated $3.87M sold.

Based on aggregated 13F filings for Q4 2021.